Abstract 6641: ATG-031, a first-in-class humanized anti-CD24 antibody, demonstrates potent in vivo efficacy and repolarizes tumor-associated macrophages in the TME

CD24型 肿瘤微环境 癌症 癌症研究 间质细胞 免疫系统 医学 癌细胞 抗体 巨噬细胞 免疫学 体内 细胞毒性T细胞 免疫检查点 化学 乳腺癌 生物 免疫疗法 体外 内科学 生物技术 生物化学
作者
Peng Chen,Min Deng,Yun Liu,Jiamei Luo,Linjie Tian,Jay Mei,Bo Shan,Bing Hou
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 6641-6641
标识
DOI:10.1158/1538-7445.am2023-6641
摘要

Abstract Background: Tumor microenvironment (TME) is shaped by not only cancer cells but also a variety of resident and infiltrating cells, including stromal fibroblasts, endothelial cells and immune cells like tumor-associated macrophages (TAM) and lymphocytes (Roghayyeh et al., 2020). Most TAMs are considered as the M2 subtype with pro-tumor/anti-inflammation effects. CD24 is a small, highly glycosylated cell adhesion protein and was reported to be the dominant innate immune checkpoint in ovarian cancer and breast cancer, and acts as a novel “don’t eat me” target. CD24 is over-expressed on tumor cells and can help them avoid being engulfed by macrophages through its interaction with Siglec-10 expressed by TAM. ATG-031 is a humanized anti-CD24 monoclonal antibody that binds to CD24 with high affinity and specificity and blocks the interaction of CD24 with Siglec-10 on macrophages, enhancing macrophage-mediated phagocytosis of tumor cells. In this study, we evaluated the in vivo efficacy of ATG-031 and explored its pharmacodynamic effects. Methods: C57BL/6J mice were inoculated with wild-type (WT) MC38 cells on the left flank and MC38 cells that express human CD24 (MC38-hCD24) on the right flank. When the average tumor volume reached 120 to 140 mm3 for MC38-hCD24, mice were treated with vehicle control (PBS) or ATG-031 at 3 mg/kg intravenously twice a week for four doses. A group of mice inoculated with only MC38 tumor cells was set as the control and treated with ATG-031 by the same way. Tumor volume was measured twice a week to evaluate the efficacy of ATG-031. Tumor samples were isolated at the endpoint of this efficacy study, and a multiplex IHC staining was performed to evaluate the change of tumor-infiltrating immune cells in response to ATG-031. Results: ATG-031 treatment significantly inhibited the tumor growth of MC38-hCD24 on the right flank of mice with a tumor growth inhibition (TGI) of 60.52%. Interestingly, although the WT MC38 tumor on the left flank did not express the antigen, human CD24, ATG-031 still demonstrated efficacy in controlling the tumor growth with a TGI of 21.17%. Without the co-inoculation of MC38-hCD24, ATG-031 did not affect the WT MC38 tumor growth in the control group. Multiplex IHC staining revealed that the proportion of M1 macrophage increased in response to ATG-031 treatment, not only in MC38-hCD24 tumors but also in WT MC38 tumors on the left flank. Conclusions: ATG-031, a first-in-class anti-CD24 antibody, demonstrated potent anti-tumor activity in vivo, re-polarizing M2-like TAM to anti-tumor M1 subtype in the TME and induced systemic anti-tumor immunity. A clinical study to investigate the safety and efficacy of ATG-031 in cancer patients is being developed. Citation Format: Peng Chen, Min Deng, Yun Liu, Jiamei Luo, Linjie Tian, Jay Mei, Bo Shan, Bing Hou. ATG-031, a first-in-class humanized anti-CD24 antibody, demonstrates potent in vivo efficacy and repolarizes tumor-associated macrophages in the TME. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6641.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zcyuqing发布了新的文献求助10
1秒前
1秒前
雨墨完成签到,获得积分10
1秒前
1秒前
2秒前
hu发布了新的文献求助30
2秒前
xiaoluo完成签到,获得积分10
2秒前
hu发布了新的文献求助10
2秒前
hu发布了新的文献求助10
2秒前
2秒前
小马甲的应助被聪明晓博采纳,获得10
3秒前
如意的听露完成签到,获得积分10
3秒前
YU发布了新的文献求助10
3秒前
hh完成签到 ,获得积分10
4秒前
4秒前
sunny发布了新的文献求助10
4秒前
斯文败类的应助被独特的兔子采纳,获得10
4秒前
yanyh完成签到,获得积分10
5秒前
5秒前
6秒前
7秒前
7秒前
7秒前
Lifel发布了新的文献求助10
7秒前
初景发布了新的文献求助50
7秒前
8秒前
刘大年完成签到,获得积分10
8秒前
9秒前
9秒前
关厚朴发布了新的文献求助10
9秒前
9秒前
科目三的应助被hzz采纳,获得10
10秒前
10秒前
归亦完成签到,获得积分10
10秒前
JamesPei的应助被taly采纳,获得10
10秒前
快乐DDD完成签到,获得积分10
10秒前
在水一方的应助被yunyang采纳,获得10
11秒前
在水一方的应助被耍酷的剑身采纳,获得10
11秒前
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155816
求助须知:如何正确求助?哪些是违规求助? 9552109
关于积分的说明 21708107
捐赠科研通 7744978
什么是DOI,文献DOI怎么找? 3426225
关于科研通互助平台的介绍 2551237
邀请新用户注册赠送积分活动 2469958